China
Africa
Explore chapters and articles related to this topic
Myocarditis
Published in Andreas P. Kalogeropoulos, Hal A. Skopicki, Javed Butler, Heart Failure, 2023
George Lazaros, Emilia Lazarou, Dimitris Tousoulis
Giant cell myocarditis is an uncommon but particularly severe form of myocarditis, with rapid progression to intractable HF and frequent need for heart transplantation.4,25,26 Its incidence is estimated at 0.13 per 100,000 people annually and seems to increase over time; it is detected approximately in 3–5.6% of all myocarditis autopsies.4,27–29 The mean age at onset is 43 and, in 19% of cases, an associated autoimmune disorder is reported.4,29 Fulminant myocarditis is detected in 10% of patients undergoing EMB for recent-onset cardiomyopathy.17 It is a distinct clinical entity with approximately 7% in-hospital mortality. However, patients who survive the acute event with aggressive hemodynamic support have excellent long-term prognosis with full recovery of cardiac function.17 Finally, acute fulminant necrotizing myocarditis is a very uncommon and often fatal form of acute myocarditis presenting with rapidly progressing symptoms, leading to HF and shock. In contrast to other forms of eosinophilic myocarditis (such as hypersensitivity myocarditis), the exclusive target is the heart without concomitant multiorgan involvement.30
Rare Diseases Drug Development
Published in Wei Zhang, Fangrong Yan, Feng Chen, Shein-Chung Chow, Advanced Statistics in Regulatory Critical Clinical Initiatives, 2022
Shein-Chung Chow, Shutian Zhang, Wei Zhang
Velcade® (Bortezomib) is an antineoplastic agent (a proteasome inhibitor) indicated for the treatment of multiple myeloma and mantle cell lymphoma (see Table 1.1). Multiple myeloma is the second most common cancer (an incurable cancer) of the blood, representing approximately 1% of all cancers and 2% of all cancer deaths. It is estimated that approximately 45,000 Americans have multiple myeloma with about 15,000 new cases diagnosed each year. Only about percent of multiple myeloma patients survive longer than five years with the disease. Although the disease is predominantly a cancer of the elderly (the average age at diagnosis is 70 years of age) recent statistics indicate both increased incidence and younger age of onset. Thus, multiple myeloma is considered a rare disease and meet the requirement for Fast-Track designation for expedited review.
Hyperkinetic Movement Disorders
Published in Philip B. Gorelick, Fernando D. Testai, Graeme J. Hankey, Joanna M. Wardlaw, Hankey's Clinical Neurology, 2020
Morales-Briceno Hugo, Victor S.C. Fung, Annu Aggarwal, Philip Thompson
Age of onset: Infancy (birth to 2 years).Childhood (3–12 years).Adolescence (13–20 years).Early adulthood (21–40 years).Late adulthood (>40 years).
Association between participation in the Northern Finland Birth Cohorts and cardiometabolic disorders
Published in Annals of Medicine, 2023
Martta Kerkelä, Mika Gissler, Tanja Nordström, Olavi Ukkola, Juha Veijola
Table 2 reports the cumulative incidences % (N), Pearson’s chi-square statistics, and risk ratios (RR) with 95% confidence intervals (CI) of all hospital-treated cardiovascular disorders of NFBC1966 with the comparison cohort at age 7 to 50 years. No significant differences in cumulative incidences between NFBC1966 and the comparison cohort were found for cardiometabolic disorders. Female members of NFBC1966 had a lower age of onset of coronary artery disease (median age of onset 42.5 years vs 45.8 years; Q:3.85, p = 0.0.049), diabetes mellitus (median age of onset 38.1 years vs 41.7 years; Q:8.28, p = 0.004) and any cardiometabolic disorder (median age of onset 42.1 years vs 43.1 years; Q:4.16, p = 0.041) compared to the comparison cohort (Figure 1, Table 3). No difference in cumulative incidences or age of onset in different types of diabetes mellitus from age 22 to 50 years between NFBC1966 and the comparison cohort was found (Table 4).
Assessment of compliance and relapse in patients with schizophrenia before and after the onset of COVID-19 pandemic
Published in International Journal of Psychiatry in Clinical Practice, 2023
Medhat M. Bassiony, Mohammad G. Sehlo, Eman F. Ibrahim, Alaa E. Zayed, Samar A. Atwa
This study included 70 patients with schizophrenia and 51% of them were less than 35 years old with a mean age of 36.2 ± 9.95. Seventy-seven per cent were males and about two-thirds had secondary school or university education. More than half of the patients were single and about one-third were married. Three out of four were not working and 64% had rural residence. Forty-two percent were smokers and 2% were ex-smokers. The age of onset of schizophrenia was 22.73 ± 6.9 years old and the illness duration was 13.4 ± 9 years. The number of hospitalisations was 1.5 ± 2.5 and 58% of the patients had positive family history of psychiatric illness. Twenty-seven percent of the patients had positive consanguinity. Moreover, 12 patients (13%) with schizophrenia had medical diseases: 4 patients had D.M., 3 patients had HCV, 2 patients had hypertension, 2 patients had bronchial asthma, 1 patient had renal disease, 1 patient had hypothyroidism, and 1 patient had irritable bowel syndrome. Some of these patients had more than one medical disease.
Biologic treatment of psoriasis in oncologic patients
Published in Expert Opinion on Biological Therapy, 2022
Lluís Rusiñol, Gemma Camiña-Conforto, Luis Puig
The mean age at onset of cancer was 54.5 years in the 37 patients of the series by Mastorino et al. and 56.3 years in the 38 additional cases[28,38–49]. The details, neoplasms, and treatments of psoriasis in those patients are summarized in Table 5. Among the 75 additional cases from the literature, 68 patients would fit in our precedent cancer group (PC), and the remaining 7 cases in our intercurrent cancer group (IC). In the PC group, 85 biologic treatments were prescribed; in some cases, biologic treatment was switched during follow-up. Anti-TNFα agents were prescribed in 20 patients, ustekinumab in 12, anti-IL-23 agents were prescribed in 8, and IL-17 inhibitors were initiated in 45 patients. In the IC group, 7 biologic treatments were being administered when cancer was diagnosed: anti-TNFα agents in 2 patients, ustekinumab in 1, anti-IL-17 biologics in 4, and no patient was receiving anti-IL-23 treatment.